Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975085 · ClinicalTrials.gov registry record · Phase 2
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 781
- Enrollment target
NCT06975085: Completed Phase 2 study, sponsored by University of Colorado, Denver.
NCT06975085 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 781 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (487% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06975085, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 781 participants
- Enrollment target
Study Summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
Primary Outcome
Participants are asked whether they agree or disagree with their Gail Model risk estimate. Risk rejection was defined as disagreement the estimate. An open text box allows them to write the risk number that they believe is accurate for them.
Interventions
- BEHAVIORAL Presentation of a personal breast cancer risk estimate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
What the finished NCT06975085 record still lists
NCT06975085 is an interventional study that assigns participants to a tested intervention. The registered 781 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (487% higher).
The record links to 0 conditions, and to 1 intervention - of which Presentation of a personal breast cancer risk estimate is the first listed.
NCT06975085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06975085 about?
NCT06975085 is a clinical study titled "Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study". The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
What is the current status of trial NCT06975085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 781 participants. The study started on 2025-04-16. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06975085?
The interventions under investigation include: Presentation of a personal breast cancer risk estimate (BEHAVIORAL).
Who is sponsoring clinical trial NCT06975085?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06975085's enrollment target sits among peer trials
781 41st of 2000 higher than 1,960 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI